Aliases & Classifications for Capillary Disease

MalaCards integrated aliases for Capillary Disease:

Name: Capillary Disease 12 15
Disease of Capillaries 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1271
ICD10 33 I78 I78.9
ICD9CM 35 448
UMLS 73 C0155765

Summaries for Capillary Disease

Disease Ontology : 12 A vascular disease that is located in the capillaries.

MalaCards based summary : Capillary Disease, also known as disease of capillaries, is related to burns and eosinophilic gastroenteritis, and has symptoms including petechiae of skin An important gene associated with Capillary Disease is IL2 (Interleukin 2), and among its related pathways/superpathways are Photodynamic therapy-induced NF-kB survival signaling and Cytokines and Inflammatory Response. The drugs Bosentan and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include the capillaries, bone and bone marrow.

Related Diseases for Capillary Disease

Diseases related to Capillary Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Related Disease Score Top Affiliating Genes
1 burns 10.5 ALB CSF2
2 eosinophilic gastroenteritis 10.5 ALB CSF2
3 pure red-cell aplasia 10.5 ALB IL2
4 hydrops, lactic acidosis, and sideroblastic anemia 10.4 ALB SERPING1
5 smallpox 10.4 CSF2 IL2
6 filariasis 10.3 ALB IL2
7 pulmonary sarcoidosis 10.2 CSF2 IL2
8 capillary leak syndrome 10.2 ALB CSF2 IL2
9 leukocyte disease 10.2 ALB CSF2 IL2
10 acquired immunodeficiency syndrome 10.2 ALB CSF2 IL2
11 immune system disease 10.2 ALB CSF2 IL2
12 lymphoma, hodgkin, classic 10.2 CSF2 IL2
13 mastitis 10.2 ALB CSF2
14 mucositis 10.1 CSF2 IL2
15 myeloma, multiple 10.1 ALB CSF2 IL2
16 microscopic colitis 10.0 ATP12A IL2
17 primary bacterial infectious disease 10.0 ALB IL2
18 hereditary hemorrhagic telangiectasia 9.9
19 fungal esophagitis 9.9 ATP12A ATP4A
20 bladder calculus 9.9 ATP12A ATP4A
21 gastrointestinal neuroendocrine benign tumor 9.9 ATP12A ATP4A
22 neonatal candidiasis 9.9 ATP12A ATP4A
23 photoallergic dermatitis 9.9 ATP12A ATP4A
24 squamous papillomatosis 9.9 ATP12A ATP4A
25 acute laryngitis 9.9 ATP12A ATP4A
26 gastroduodenal crohn's disease 9.9 ATP12A ATP4A
27 gastric neuroendocrine neoplasm 9.9 ATP12A ATP4A
28 toxic megacolon 9.9 ATP12A ATP4A
29 aspiration pneumonitis 9.9 ATP12A ATP4A
30 postsurgical hypothyroidism 9.9 ATP12A ATP4A
31 gastric antral vascular ectasia 9.9 ATP12A ATP4A
32 esophageal candidiasis 9.9 ATP12A ATP4A
33 duodenitis 9.9 ATP12A ATP4A
34 rumination disorder 9.9 ATP12A ATP4A
35 bile reflux 9.9 ATP12A ATP4A
36 granulomatous gastritis 9.9 ATP12A ATP4A
37 active peptic ulcer disease 9.9 ATP12A ATP4A
38 laryngeal disease 9.9 ATP12A ATP4A
39 ischemic neuropathy 9.9 ATP12A ATP4A
40 peptic esophagitis 9.9 ATP12A ATP4A
41 duodenal disease 9.9 ATP12A ATP4A
42 dyskinesia of esophagus 9.9 ATP12A ATP4A
43 hernia, hiatus 9.9 ATP12A ATP4A
44 congenital disorder of deglycosylation 9.8 ATP12A ATP4A
45 anismus 9.8 ATP12A ATP4A
46 esophageal atresia/tracheoesophageal fistula 9.8 ATP12A ATP4A
47 laryngitis 9.8 ATP12A ATP4A
48 laryngeal tuberculosis 9.8 ATP12A ATP4A
49 lymphocytic colitis 9.8 ATP12A ATP4A
50 clostridium difficile colitis 9.8 ATP12A ATP4A

Graphical network of the top 20 diseases related to Capillary Disease:



Diseases related to Capillary Disease

Symptoms & Phenotypes for Capillary Disease

UMLS symptoms related to Capillary Disease:


petechiae of skin

Drugs & Therapeutics for Capillary Disease

Drugs for Capillary Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 264)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4,Phase 2 147536-97-8 104865
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
3
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 53-03-2 5865
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
7
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613
8
Clarithromycin Approved Phase 4,Phase 2,Phase 3 81103-11-9 84029
9
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
10
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
11
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
12
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
13
Azathioprine Approved Phase 4,Phase 3,Not Applicable 446-86-6 2265
14
Hydroxychloroquine Approved Phase 4 118-42-3 3652
15
Vincristine Approved, Investigational Phase 4,Phase 2,Phase 3 2068-78-2, 57-22-7 5978
16
Bisoprolol Approved Phase 4 66722-44-9 2405
17
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
18
Captopril Approved Phase 4 62571-86-2 44093
19
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
20
Cilazapril Approved Phase 4 88768-40-5, 92077-78-6 56329 56330
21
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
22
Enalaprilat Approved Phase 4 76420-72-9 6917719
23
Eprosartan Approved Phase 4 133040-01-4 5281037
24
Fosinopril Approved Phase 4 98048-97-6 55891
25
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
26
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
27
Losartan Approved Phase 4 114798-26-4 3961
28
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
29
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
30
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
31
Ramipril Approved Phase 4 87333-19-5 5362129
32
Spirapril Approved Phase 4 83647-97-6 5311447
33
Trandolapril Approved Phase 4 87679-37-6 5484727
34
Caffeic acid Experimental, Investigational Phase 4,Phase 3 331-39-5 1549111
35
Candesartan Experimental Phase 4 139481-59-7 2541
36 Antihypertensive Agents Phase 4,Phase 2
37 Endothelin Receptor Antagonists Phase 4,Phase 2
38 Antiemetics Phase 4,Phase 2,Phase 3,Not Applicable
39 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
40 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
41 Antioxidants Phase 4,Phase 2,Phase 3,Early Phase 1
42 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
43 BB 1101 Phase 4,Phase 2,Phase 3
44 Dexamethasone acetate Phase 4,Phase 2,Phase 3 1177-87-3
45 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Not Applicable
46 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
47 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
48 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
49 Hormones Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 352)
# Name Status NCT ID Phase Drugs
1 The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis Unknown status NCT02480335 Phase 4 bosentan
2 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
3 Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research(VOYAGER)Study Completed NCT00460213 Phase 4 Valsartan 80mg daily;Valsartan 160mg daily
4 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Completed NCT02249897 Phase 4 CHOLESTYRAMINE
5 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
6 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
7 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT01390649 Phase 4
8 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
9 A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
10 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
11 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
12 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
13 NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients Recruiting NCT02817360 Phase 4 RAS-antagonist and beta-blocker up-to maximal dosages
14 The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
15 Immunomodulation With Romiplostim in Young Adults With ITP Recruiting NCT02760251 Phase 4 romiplostim
16 Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment Active, not recruiting NCT02614898 Phase 4
17 Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS Active, not recruiting NCT02574403 Phase 4 eculizumab
18 Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura Not yet recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
19 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP) Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
20 Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Withdrawn NCT01754545 Phase 4 Octaplas infusion and placebo (group 1);Octaplas infusion and placebo (group 2)
21 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
22 A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy Unknown status NCT02391272 Phase 3 rhTPO
23 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy Unknown status NCT02270801 Phase 3 rhTPO
24 Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
25 Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP Unknown status NCT01805648 Phase 3 rhTPO
26 The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP) Unknown status NCT00909077 Phase 3 Dexamethasone;Dexamethasone and Rituximab
27 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
28 Effects of Saxagliptin on Endothelial Function Completed NCT01319357 Phase 3 Saxagliptin;Placebo
29 Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch Completed NCT00275509 Phase 3 Thymoglobulin;Daclizumab;Mycophenolate mofetil;Tacrolimus;Dexamethasone;Prednisone;Cytogam
30 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
31 Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) Completed NCT02868099 Phase 3 Romiplostim;Placebo
32 Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone Completed NCT02914054 Phase 2, Phase 3 High dose Dexamethasone pulses;Prednisone
33 Caffeic Acid Tablets as a Second-line Therapy for ITP Completed NCT02351622 Phase 3 Caffeic acid;Dexamethasone;Placebo
34 Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura Completed NCT02553317 Phase 3
35 An Investigation of rhTPO With Different Frequencies in the Management of ITP Completed NCT02139501 Phase 3 Recombinant Human Thrombopoietin (rhTPO)
36 An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
37 Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia Completed NCT02334813 Phase 3 Prednisone;Dexamethasone
38 A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT02201290 Phase 3 Eltrombopag Tablets;Eltrombopag PfOS
39 A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT02076412 Phase 3 Fostamatinib Disodium 100mg;Placebo;Fostamatinib Disodium 150mg
40 A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT02076399 Phase 3 Fostamatinib Disodium 100mg;Placebo;Fostamatinib Disodium 150mg
41 rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP Completed NCT01734044 Phase 3 recombinant human thrombopoietin (rhTPO); dexamethasone;Dexamethasone
42 Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients Completed NCT01730352 Phase 2, Phase 3 H. pylori triple therapy
43 Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) Completed NCT01438840 Phase 3 Avatrombopag;Placebo;Standard of care
44 Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia Completed NCT01349790 Phase 3 NewGam
45 rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP Completed NCT01525836 Phase 3 rituximab; recombinant human thrombopoietin (rhTPO);Rituximab
46 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. Completed NCT01520909 Phase 3 Eltrombopag;Placebo
47 Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) Completed NCT01506414 Phase 3 rhTPO in combination with Rituximab
48 Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients Completed NCT01444417 Phase 3 Romiplostim;Placebo
49 Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) Completed NCT01410916 Phase 2, Phase 3 Eculizumab (Soliris®)
50 A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura Completed NCT01071954 Phase 3

Search NIH Clinical Center for Capillary Disease

Genetic Tests for Capillary Disease

Anatomical Context for Capillary Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Capillary Disease:

19
The Capillaries

MalaCards organs/tissues related to Capillary Disease:

41
Bone, Bone Marrow, Endothelial, Testes, Kidney, B Cells, T Cells

Publications for Capillary Disease

Articles related to Capillary Disease:

# Title Authors Year
1
Growth hormone, sorbitol, and diabetic capillary disease. ( 4102056 )
1971
2
Growth hormone, sorbitol, and diabetic capillary disease. ( 4100908 )
1971

Variations for Capillary Disease

Expression for Capillary Disease

Search GEO for disease gene expression data for Capillary Disease.

Pathways for Capillary Disease

Pathways related to Capillary Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.76 CSF2 IL2
2 10.1 CSF2 IL2

GO Terms for Capillary Disease

Cellular components related to Capillary Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.02 ALB ATP4A CSF2 IL2 SERPING1

Biological processes related to Capillary Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 potassium ion import GO:0010107 9.37 ATP12A ATP4A
2 ATP hydrolysis coupled proton transport GO:0015991 9.32 ATP12A ATP4A
3 cellular sodium ion homeostasis GO:0006883 9.26 ATP12A ATP4A
4 cellular potassium ion homeostasis GO:0030007 9.16 ATP12A ATP4A
5 sodium ion export across plasma membrane GO:0036376 8.96 ATP12A ATP4A
6 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 8.62 ATP12A ATP4A

Molecular functions related to Capillary Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
2 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Capillary Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....